Our new Cryptocurrency section has arrived! Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 7,217.00
Bid: 7,223.00
Ask: 7,225.00
Change: -58.00 (-0.80%)
Spread: 2.00 (0.03%)
Open: 7,100.00
High: 7,300.00
Low: 7,013.00
Yest. Close: 7,275.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

RNS Alerts are a premium feature

Login to your account

myTerminal is a premium feature

Login to your account

Don't have an account? Click here to register.

UPDATE 1-Safety data on AstraZeneca anaemia drug points to potential use in dialysis

Fri, 8th Nov 2019 19:52

(Adds quotes, further details about drug, potential sales)

FRANKFURT, Nov 8 (Reuters) - AstraZeneca said that
safety data on roxadustat underpinned the British drugmaker's
hopes for the anaemia drug to become a standard treatment for
patients with kidney disease.

It said pooled data from several late-stage trials showed
that roxadustat did not increase the risk of potentially deadly
cardiovascular complications like heart attacks and strokes when
used instead of epo, which is the standard treatment for
dialysis patients against lack of red blood cells from kidney
disease.

For a subgroup of patients that had just recently gone on
dialysis the cardiovascular risk was about one third lower for
patients on roxadustat compared with those on epo, it added.

In a release on Thursday, AstraZeneca already said the drug
was shown to be better than epo - which is short for the hormone
erythropoietin - at improving the red blood cell count in
patients on dialysis.

AstraZeneca hopes that roxadustat will in future be cleared
for use to fight anaemia in kidney disease patients that do not
yet require blood cleansing via dialysis.

This group is currently not given epo because of the
cardiovascular risks associated with the hormone.

Trial data showed that giving roxadustat against anaemia did
not increase cardiovascular risk, Astra said.

Astra executive Mene Pangalos said the results "reinforce
our confidence in the potential of roxadustat to address
significant unmet medical needs among patients with anaemia from
chronic kidney disease, particularly for those who have recently
started dialysis".

The drug, for which AstraZeneca already secured initial
Chinese market approval last year, is expected to reach annual
revenue of $870 million by 2024, according to Refinitiv data on
analyst estimates.

Deutsche Bank analysts said this month a favourable safety
profile could propel the drug to blockbuster sales, an industry
term for the $1 billion mark in annual revenues. AstraZeneca
would not disclose sales projections.

The company said it would file for U.S. regulatory approval
this year.

Certain regional rights on the drug are held by FibroGen
and Astellas Pharma.
(Reporting by Ludwig Burger; Editing by Elaine Hardcastle)

More News

UPDATE 1-UK Plc shares skyrocket on Johnson's sweeping win

* FTSE 100 up 1%, FTSE 250 jumps 4.2%* Utilities, banks and retailers top risers* Utility sector soars as Corbyn steps down as Labour leader* National Grid, United Utilities up 5%* RBS, Lloyds jump more than 10% (Updates stock prices)By Thyagaraju A...

13 Dec 19 08:49

Thursday broker round-up

(Sharecast News) - Synthomer: JP Morgan upgrades to neutral with a target price of 300p.

12 Dec 19 13:38

UK BROKER RATINGS SUMMARY: Bank Of America Upgrades HSBC To Buy

UK BROKER RATINGS SUMMARY: Bank Of America Upgrades HSBC To Buy

12 Dec 19 09:32

AstraZeneca Receives Marketing Authorization In China For Imfinzi

AstraZeneca Receives Marketing Authorization In China For Imfinzi

12 Dec 19 08:35

AstraZeneca gets Imfinzi approval in China

(Sharecast News) - AstraZeneca announced on Thursday that it has received marketing authorisation from China's National Medical Products Administration (NMPA) for 'Imfinzi' - durvalumab - for the treatment of patients with unresectable, stage 3 non-small cell lung cancer (NSCLC), whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy (CRT).

12 Dec 19 07:32

Astra's Trastuzumab Deruxtecan Achieves Tumour Response Rate Of 60.9%

Astra's Trastuzumab Deruxtecan Achieves Tumour Response Rate Of 60.9%

11 Dec 19 13:41

AstraZeneca-Daiichi drug halts cancer for months in first readout

Dec 11 (Reuters) - An experimental cancer drug developed by AstraZeneca and Daiichi Sankyo kept metastatic breast cancer at bay for months in women who had exhausted other treatment options, its first clinical study showed.Patients on trastuzumab ...

11 Dec 19 13:00

Tuesday broker round-up

(Sharecast News) - ASOS: HSBC upgrades to buy with a target price of 3,615p.

10 Dec 19 08:29

DeepMatter shares surge as it announces AstraZeneca collaboration

(Sharecast News) - DeepMatter shares surged on Monday, after it announced a collaboration with AstraZeneca to use digital technologies to improve the productivity and reproducibility of compound synthesis.

9 Dec 19 14:07

UK WINNERS & LOSERS SUMMARY: Tullow Plunges On Output Guidance Reset

UK WINNERS & LOSERS SUMMARY: Tullow Plunges On Output Guidance Reset

9 Dec 19 10:50

UPDATE 2-UK shares weaken, Tullow loses half its market cap

* FTSE 100, FTSE 250 down 0.1%* Tesco outshines the main index* Some domestic stocks gain on election optimism* Tullow Oil plummets after co cancels dividend, CEO exits (Adds company news items, updates share moves)By Muvija M and Shashwat AwasthiDe...

9 Dec 19 09:23

DeepMatter Shares Surge On AstraZeneca DigitalGlassware Collaboration

DeepMatter Shares Surge On AstraZeneca DigitalGlassware Collaboration

9 Dec 19 09:15

Positive Results From AstraZeneca Trial Of Calquence Drug In Leukaemia

Positive Results From AstraZeneca Trial Of Calquence Drug In Leukaemia

9 Dec 19 06:51

AstraZeneca, Merck Get Marketing Authorization In China For Lynparza

AstraZeneca, Merck Get Marketing Authorization In China For Lynparza

5 Dec 19 08:31

AstraZeneca's Lynparza approved for use in China

(Sharecast News) - Biopharmaceutical company AstraZeneca announced on Thursday that Lynparza had been approved in China as a first-line maintenance therapy in BRCA-mutated advanced ovarian cancer.

5 Dec 19 08:27

Login to your account

Don't have an account? Click here to register.